ClinicalTrials.gg
CompletedNCT02660112Updated Dec 5, 2019Results posted

(+) Epicatechin to Treat Friedreich's Ataxia

A Phase 2 interventional study of (+)-Epicatechin in Friedreich's Ataxia, sponsored by Ralitza Gavrilova. Completed at 1 site in United States. Open to participants aged 10 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-12-05.

Sponsored by Ralitza Gavrilova · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
10 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
42nd of 49
10 · median 32
Started
2016
with 2 others
Phase 2
14 of 71
3 open now
Registered
26th of 71
by date

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 42nd largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2016, is one of 14 in phase 2, and was the 26th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 10 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

This 24-week study will test the safety and effectiveness of synthetically produced (+) Epicatechin in treating patients who have Friedreich's Ataxia, a neurological disorder.

03

Conditions studied

  • Friedreich's Ataxia

Browse trials for

04

Who can participate

Ages eligible
10 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Friedreich's Ataxia (FA) by Frataxin genetic testing and/or Frataxin enzyme analysis
  • Between age 10 and 50 years of age, inclusive
  • Body weight of 25 kilograms or higher
  • Minimum of one affected organ (cardiac or neurological) system, as evidenced by clinical signs/symptoms
  • Disease duration ≤7 years, based on onset date of FA symptoms
  • Has no known to gadolinium contrast such as severe allergy or \<30 ml/min/m\^2.
  • Has no known contraindication to non-contrast Magnetic Resonance Imaging (MRI) evaluation such as pacemaker or magnetically active metal fragments.
  • Women of childbearing age must:

    • Have a negative pregnancy human chorionic gonadotropin test prior to receiving study drug.
    • Agree to use for the duration of the study drug dosing, plus 1 month after completion of the study.

Exclusion criteria

Exclusion Criteria:

  • Advanced cardiac failure, (NYHA) Classification Scale-Class IV (advanced stage heart failure)
  • comorbidities that may also lead to cardiomyopathy, for example long standing hypertension, familial cardiomyopathy.
  • Clinically significant comorbidities that would, in the opinion of the investigators, compromise the interpretation of test results.
  • Pregnant, breast-feeding or planning to become pregnant during study timeframe.
  • Patients with to regadenoson, i. e. second- or third-degree atrioventricular (AV) block or sinus node dysfunction. Has received an drug within thirty (30) days of baseline visit.
  • Thrombocytopenia (\<125 x 10\^9/Liter) or prolonged /Partial Thromboplastin Time (PT/PTT) at baseline.
  • Clinically significant hypotension (systolic blood pressure \<90) due to heart failure or other conditions.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    (+)-Epicatechin

    Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks

    Drug: (+)-Epicatechin

Interventions

  • Drug(+)-Epicatechin

    Drug page: (+)-epicatechinStudies of (+)-epicatechin(+)-epicatechin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score

    The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed (8MW), the 9-hole peg test (9HPT), PATA rate (assesses speech speed by repetitions of pronouncing "PaTa" ) and low-contrast letter acuity. FARS is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed (8MW), the 9-hole peg test (9HPT), PATA rate and low-contrast letter acuity. The scores from the three subscales are added to generate a total score ranging from 0 to 159, with a higher score indicating a greater level of disability.

    Time frame: Baseline, 24 weeks

  2. Change in Ventricular Hypertrophy as Shown on Cardiac MRI

    Left ventricular mass and left ventricular (LV) mass indexed to body surface area estimated by Left Ventricle (LV)cavity dimension and wall thickness at end-diastole. Normal values of LV mass indexed to body surface area are found to be 49-115 gL/m2 in men and 43-95 g/m2 in women.

    Time frame: Baseline, 24 weeks

07

Results

Posted Dec 5, 2019

Participant flow

Participant flow — Overall Study
Milestone(+)-Epicatechin
Started10
Completed10
Not completed0

Outcome measures

PrimaryChange From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score

The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed (8MW), the 9-hole peg test (9HPT), PATA rate (assesses speech speed by repetitions of pronouncing "PaTa" ) and low-contrast letter acuity. FARS is made up of a measure of ataxia, an activities of daily living subscale and a neurological subscale. This scale also includes the 8m walk at maximum speed (8MW), the 9-hole peg test (9HPT), PATA rate and low-contrast letter acuity. The scores from the three subscales are added to generate a total score ranging from 0 to 159, with a higher score indicating a greater level of disability.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score
score on a scale(+)-Epicatechin
Change From Baseline in Friedreich Ataxia Rating Scale (FARS) Composite Score55.0 ± 18.72
Statistical analysis
  • (+)-Epicatechin · Wilcoxon (Mann-Whitney) · p = 0.336
PrimaryChange in Ventricular Hypertrophy as Shown on Cardiac MRI

Left ventricular mass and left ventricular (LV) mass indexed to body surface area estimated by Left Ventricle (LV)cavity dimension and wall thickness at end-diastole. Normal values of LV mass indexed to body surface area are found to be 49-115 gL/m2 in men and 43-95 g/m2 in women.

Time frame:
Baseline, 24 weeks
Reported as:
Mean · mL/m2
Change in Ventricular Hypertrophy as Shown on Cardiac MRI
mL/m2(+)-Epicatechin
Change in Ventricular Hypertrophy as Shown on Cardiac MRI55.9 ± 9.49

Adverse events

Collected over Adverse Events were collected over a 24 week time period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(+)-Epicatechin0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
Event(+)-Epicatechin
Transient worsening of migraineNervous system disorders3/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)(+)-Epicatechin
Median14.5 (10 to 50)
Sex: Female, Male
Sex: Female, Male(Participants)(+)-Epicatechin
Female4
Male6
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)(+)-Epicatechin
Region of Enrollment
Region of Enrollment(participants)(+)-Epicatechin
United States10
08

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Qureshi MY, Patterson MC, Clark V, Johnson JN, Moutvic MA, Driscoll SW, Kemppainen JL, Huston J 3rd, Anderson JR, Badley AD, Tebben PJ, Wackel P, Oglesbee D, Glockner J, Schreiner G, Dugar S, Touchette JC, Gavrilova RH. Safety and efficacy of (+)-epicatechin in subjects with Friedreich's ataxia: A phase II, open-label, prospective study. J Inherit Metab Dis. 2021 Mar;44(2):502-514. doi: 10.1002/jimd.12285. Epub 2020 Aug 31. PubMed 32677106 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2016
First posted
Jan 21, 2016
Start
Sep 2016
Primary completionActual
Dec 30, 2018
CompletionActual
Dec 30, 2018
Results first posted
Dec 5, 2019
Last update
Dec 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02660112
Lead sponsor
Ralitza Gavrilova
Collaborators
Cardero Therapeutics, Inc.
Responsible party
Ralitza Gavrilova (MD, Sponsor-Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Jan 21, 2016
Start date
Sep 2016
Primary completion
Dec 30, 2018
Completion
Dec 30, 2018
Results posted
Dec 5, 2019
Last update
Dec 5, 2019

Study contacts

Ralitza H Gavrilova, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: (+)-epicatechin

Start the discussion